Asthma
Conditions
Interventions
Budesonide group Budesonide 200micro
g two inhalations bid (morning and evening)
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Signed informed consent by the patient - Outpatient, man or woman, 20 years or older - Diagnosis of asthma - Sputum over the past 8 weeks patien
Exclusion criteria
Exclusion criteria: - Patients with a history of hypersensitivity (including contact dermatitis) to any ingredient contained in the study drugs - Patients with infections with no available effective antimicrobial drugs or with deep seated mycosis - Patients with tuberculosis - Respiratory infection, judged by the investigator as an infection affecting the asthma, within 8 weeks prior to enrollment - Use of any beta-blocking agents - Treatment with oral, parenteral or rectal steroids within 30 days prior to enrollment - Any significant disease or disorder judged by the investigator - Current or previous with a smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in m-CASA-Q efficacy(%) from before to after 8 weeks treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in lung function (%FEV1/%PEF) from before to after 8 weeks treatment Changes in eosinophil and neutrophil from before to after 8 weeks treatment Changes in ECP and mucin from before to after 8 weeks treatment | — |
Countries
Japan
Contacts
Public ContactJun Tamaoki
Tokyo Women's Medical University Respiratory Medicine
Outcome results
None listed